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Abstract
Background: Decision makers in many jurisdictions use cost-effectiveness estimates as an aid for selecting
interventions with an appropriate balance between health benefits and costs. This systematic literature review aims
to provide an overview of published cost-effectiveness models in major depressive disorder (MDD) with a focus on
the methods employed. Key components of the identified models are discussed and any challenges in developing
models are highlighted.
Methods: A systematic literature search was performed to identify all primary model-based economic evaluations
of MDD interventions indexed in MEDLINE, the Cochrane Library, EMBASE, EconLit, and PsycINFO between January
2000 and May 2010.
Results: A total of 37 studies were included in the review. These studies predominantly evaluated antidepressant
medications. The analyses were performed across a broad set of countries. The majority of models were decision-
trees; eight were Markov models. Most models had a time horizon of less than 1 year. The majority of analyses
took a payer perspective. Clinical input data were obtained from pooled placebo-controlled comparative trials,
single head-to-head trials, or meta-analyses. The majority of studies (24 of 37) used treatment success or symptom-
free days as main outcomes, 14 studies incorporated health state utilities, and 2 used disability-adjusted life-years. A
few models (14 of 37) incorporated probabilities and costs associated with suicide and/or suicide attempts. Two
models examined the cost-effectiveness of second-line treatment in patients who had failed to respond to initial
therapy. Resource use data used in the models were obtained mostly from expert opinion. All studies, with the
exception of one, explored parameter uncertainty.
Conclusions: The review identified several model input data gaps, including utility values in partial responders,
efficacy of second-line treatments, and resource utilisation estimates obtained from relevant, high-quality studies. It
highlighted the differences in outcome measures among the trials of MDD interventions, which can lead to
difficulty in performing indirect comparisons, and the inconsistencies in definitions of health states used in the
clinical trials and those used in utility studies. Clinical outcomes contributed to the uncertainty in cost-effectiveness
estimates to a greater degree than costs or utility weights.
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Major depressive disorder (MDD) is a highly prevalent
condition estimated to affect 2.3% of the global popula-
tion [1]. MDD is associated with decreased patient well-
being [2], significant burden on health care costs, and
productivity losses [3]. It is projected that by the year
2020, depression will rank second in disease burden
measured by disability-adjusted life-years [4]. The most
common and generally accepted treatment options for
patients with MDD include pharmacotherapy, psy-
chotherapy, and pharmacotherapy in combination with
psychotherapy [5]. A variety of pharmacotherapies exist
for treating MDD; traditionally, these fall into pharma-
cological classes, such as tricyclic antidepressants
(TCAs), tetracyclic antidepressants (non-selective seroto-
nin and norepinephrine reuptake inhibitors), selective
serotonin reuptake inhibitors (SSRIs), selective norepi-
nephrine reuptake inhibitors (NRIs), selective serotonin
and norepinephrine reuptake inhibitors (SNRIs), monoa-
mine oxidase inhibitors (MAOIs) (including irreversible
MAOIs and reversible inhibitors of monoamine oxidase
A [RIMAs]), agonists of the melatonin receptor (MT
agonists), and other antidepressants [6]. In addition, a
wide range of psychotherapeutic options are available,
including behavioural therapy, interpersonal therapy,
cognitive behavioural therapy (CBT), and the cognitive
behavioural analysis system of psychotherapy [6].
With limitations on health care spending, it is impor-
tant to allocate resources to interventions that are seen
to maximise cost-effectiveness. Evaluating the cost-effec-
tiveness of alternative treatment options in MDD can
shape policies concerning formulary coverage and reim-
bursement. A significant number of models evaluating
the cost-effectiveness of alternative MDD strategies have
been developed. Some of these were examined by Bar-
rett and colleagues [7] in their systematic review of pub-
lished economic evaluations of interventions for
depression. However, no systematic review of the deci-
sion-analytic models in MDD has been published
recently.
The objectives of this systematic review were to iden-
tify published decision-analytic models evaluating the
cost-effectiveness of pharmacological treatments in
MDD; to examine the variation and frequency of meth-
ods employed, highlighting advantages and disadvan-
tages in these methodologies; and to identify specific
areas in the MDD cost-effectiveness literature that mer-
ited further research to allow improvement in the qual-
ity of the economic evaluations.
Methods
A systematic literature search was performed to identify
relevant articles with abstracts indexed in MEDLINE,
the Cochrane Library, EMBASE, EconLit, and
PsycINFO. A search strategy was developed for each
electronic database using a combination of Medical Sub-
ject Heading (MeSH) and free-text terms, grouped into
the following categories: disease, interventions, econom-
ics, and study type. MeSH terms used were ‘Depressive
Disorder, Major’, ‘Drug Therapy’, ‘Antidepressive
Agents’, ‘Costs and Cost Analysis’, ‘Cost-Benefit Analy-
sis’, ‘Economics, Hospital’, ‘Economics, Medical’, ‘Eco-
nomics, Nursing’, ‘Economics, Pharmaceutical’, ‘Fees and
Charges’, ‘Health Resources/utilization’. The search was
limited to articles published in the English language
from January 2000 to May 2010. The search strategies
were developed by an information specialist with input
from authors; full details can be made available on
request. Reference lists of identified review articles were
checked for relevant studies.
Predefined inclusion criteria were used to determine the
selection of the studies. The studies of interest included
model-based economic evaluations of pharmacological
interventions in MDD (e.g., Markov models, decision-tree
models, and models based on mathematical equations).
Excluded studies were reviews, editorials, resource use and
cost studies, and economic evaluations alongside a clinical
trial or those evaluating non-pharmacological interven-
tions only. Study inclusion was performed by the authors
and disagreements were resolved by consensus. Data
extraction included author and year, country of analysis,
analysis type and model structure, analysis time horizon
and perspective, treatment comparators, primary out-
comes, definitions of effectiveness, sources of primary clin-
ical data, sources of utility data, treatment of uncertainty,
and main findings. For each eligible study, data of interest
were extracted by one researcher. To ensure quality and
accuracy of the data, a second researcher verified the
extracted data with their original sources.
Results
Search Results and Study Characteristics
The search retrieved 1320 citations, 34 of which met the
s t u d yi n c l u s i o nc r i t e r i a ,a n daf u r t h e r3w e r ei d e n t i f i e d
through screening of the reference lists (Figure 1). The
characteristics of the included economic models are pre-
sented in Table 1[8-45]. Of the 37 included studies, 23
were cost-effectiveness analyses and 14 were cost-utility
analyses. The majority of the models (28 of 37) had a
decision-tree structure, eight described themselves as
Markov models [9-11,16,26,32,33,37], and one [31] did
not explicitly report the model structure.
The majority of studies (22 of 37) adopted a 6-month
time horizon; most were conducted from the health care
payer perspective (19 of 37) and were in adults with
MDD receiving first-line therapy (32 of 37).
Of the included studies, 29 examined pharmacological
interventions only, four studies evaluated non-
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therapies [10,16,22,42], two studies included compari-
sons of pharmacological treatments versus combination
therapies (i.e., pharmacotherapy and behavioural ther-
apy) [35,36], one study evaluated the prolongation of
pharmacological treatment versus no prolongation fol-
lowing response to initial therapy [32], and one study
evaluated pharmacogenetic testing for antidepressant
response [33].
The included studies represented 23 countries: Austra-
lia [22,42], Austria [23,24], Belgium [17], Brazil [30],
Canada [41], Denmark [38], Finland [19], France [13,16],
Germany [14,18,26], Italy [14,18], Japan [35], Norway
[20], Poland [14,18], Scotland [11], Singapore [45], Spain
[14,18], Sweden [14,18,29,37], Switzerland [14,18], Thai-
land [25], the Netherlands [14,18,32], United Kingdom
(UK) [12,14,18,21,27,28,36,43,44], United States (US)
[8-10,14,15,18,31,33,39,40], and Venezuela [14,18].
Modelling Approaches
Of the identified models, 28 were described as decision-
tree models. Of these, nine [17,19,20,23,25,29,38,43,45]
had a similar design based on the model structure
reported by Francois [19] (Figure 2). The decision-tree
structure used by these models consisted of two paths.
Patients with MDD entered the model in the first path
representing primary care. Patients with inadequate
response in primary care could titrate to a higher dose
or switch treatment. Patients with insufficient response
after titration and/or switching were referred to second-
ary care, represented by the second path. In the second-
ary care path, patients could have their dose titrated,
have their treatment switched, receive adjunctive ther-
apy with another agent, or be hospitalised. The model
design incorporated the rates of suicide and suicide
attempt. Most of the models used the rates of suicide
and attempted suicide reported by Khan [46], with two
models [19,20] using alternative sources. Three of the
studies [25,43,45] that adapted the model structure
reported by Francois [19] performed country-specific
modifications to better reflect local clinical practice.
Of the decision-tree models identified, six
[14,15,18,21,27,28] were based on the structure pre-
sented by Casciano [15] (Figure 3). The events modelled
following treatment failure due to lack of efficacy
included titration to maximum dosage, within-class
adjunctive therapy, between-class adjunctive therapy,
and treatment switch. Chance nodes for these events
were evaluated through consultation with clinical
experts. The analysis by Doyle and colleagues [18]
Figure 1 Flow diagram for selection of studies.
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Author, Year,
Country
Compara-tors Analysis
Type,
Model
Structure
Time
Horizon,
Perspective
Primary
Out-come
Definition of
Effective-ness
Source of
Primary
Clinical Data
Sensitivity
Analyses
Main Finding
Armstrong et
al., 2007 [8]
US
Escitalopram
vs.
sertraline
CUA;
decision-
tree
6 months,
payer
perspective
QALYs Response: ≥ 50%
improve-ment in
MADRS
8-week head-
to-head trial
Univariate,
probabilistic
Escitalopram
dominated
a sertraline
Armstrong et
al., 2008 [9]
US
Escitalopram
vs.
duloxetine
CUA;
Markov
structure;
1-week
cycle
1 year,
payer
perspective
QALWs Remission: MADRS ≤
12 or HAMD-17 ≤ 7
Pooled
analysis of 10
RCTs
Univariate,
probabilistic
Escitalopram
dominated
a duloxetine
Aziz et al.,
2005 [10]
US
MPT vs.
MECT
b
CUA;
Markov
structure;
6-month
cycle
Lifetime,
payer and
societal
perspective
QALYs Remission: not
explicitly defined
Published
literature
Univariate MECT may be more
cost-effective vs. MPT
Benedict et al.,
2010 [11]
Scotland
Primary care:
duloxetine vs.
SSRIs,
venlafaxine ER,
mirtazapine
CUA;
Markov
structure;
8-week
cycle
48 weeks,
payer
perspective
QALYs Remission and
response: HAMD-17
scale, scores not
reported
Pooled
analysis of 8
RCTs, a meta-
analysis
c
Univariate,
probabilistic
For the commonly
accepted WTP
thresholds, duloxetine
was the preferred
option
Secondary
care:
duloxetine vs.
venlafaxine ER,
mirtazapine
Pooled
analysis of 2
head-to-head
trials, a meta-
analysis
d
Duloxetine dominated
a
venlafaxine ER and
mirtazapine
Borghi and
Guest, 2000
[12]
UK
Mirtazapine vs.
amitriptyline
CEA;
decision-
tree
7 months,
payer
perspective,
societal
perspective
Treatment
success
Remission:
HAMD-17 ≤ 7
Meta-analysis
of 4 RCTs of
7-month
duration
Univariate Mirtazapine was cost-
effective vs. amitriptyline
and fluoxetine
Mirtazapine vs.
fluoxetine
6 months,
payer
perspective,
societal
perspective
Treatment
success
Response: ≥ 50%
improve-ment in 17-
HAMD
6-week head-
to-head trial
Brown et al.,
2000 [13]
France
Mirtazapine vs.
fluoxetine
CEA;
decision-
tree
6 months,
societal
perspective
Treatment
success
Response: ≥ 50%
improve-ment in 17-
HAMD, HAMD-21, or
a score of 1 or 2 on
CGI
6-week head-
to-head trial
Univariate Mirtazapine was cost-
effective vs. fluoxetine
Casciano et al.,
2001 [14]
10 countries
e
Venlafaxine ER
vs.
SSRIs,
TCAs
CEA;
decision-
tree
6 months,
payer
perspective
Treatment
success,
SFDs
f
Response: 50%
improve-ment in
HAMD or MADRS
Meta-analysis Univariate,
probabilistic
Venlafaxine ER
dominated
a SSRIs and
TCAs in 9 of the 10
countries
Casciano et al.,
2000 [15]
US
Venlafaxine ER
vs.
SSRIs,
TCAs
CEA;
decision-
tree
6 months,
payer
perspective
Treatment
success,
SFDs
f
Response: 50%
improve-ment in
HAMD or MADRS
Meta-analysis Univariate,
probabilistic
Venlafaxine ER
dominated
a SSRIs and
TCAs
Dardennes et
al., 2000 [16]
France
Preventative
strategy
g vs.
episodic
strategy
h
CUA;
Markov
structure;
8-week
cycle
12 months,
payer
perspective
QALYs Remission: HDRS-21
<8
12-month
double-blind
trial
Univariate Cost of maintenance
therapy was partially
offset by the gain from
recurrence prevention
Demyttenaere
et al., 2005
[17]
Belgium
Escitalopram
vs.
citalopram,
venlafaxine
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success
Remission: MADRS ≤
12
Meta-analysis
of three 8-
week RCTs
Univariate,
probabilistic
Escitalopram
dominated
a citalopram
and was cost-effective
vs. venlafaxine
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Doyle et al.,
2001 [18]
10 countries
e
Venlafaxine vs.
SSRIs,
TCAs
CEA;
decision-
tree
6 months,
payer
perspective
Treatment
success,
SFDs
f
Response: 50%
improve-ment in
HAMD or MADRS
2 meta-
analyses
Univariate,
probabilistic
Venlafaxine dominated
a
SSRIs and TCAs in 9 of
10 countries (inpatients);
8 of 10 countries
(outpatients)
Francois et al.,
2002 [19]
Finland
Escitalopram
vs.
citalopram,
fluoxetine,
venlafaxine
CUA;
decision-
tree
6 months,
societal
perspective
Treatment
success,
QALYs
Remission: MADRS ≤
12
8-week head-
to-head trial,
indirect
comparison
Univariate Escitalopram
dominated
a citalopram,
fluoxetine and
venlafaxine
Francois et al.,
2003 [20]
Norway
Escitalopram
vs.
citalopram,
fluoxetine,
venlafaxine
CEA;
decision-
tree
6 months,
societal
perspective
Treatment
success
Remission: MADRS ≤
12
8-week head-
to-head trial,
indirect
comparison
Univariate Escitalopram
dominated
a citalopram,
fluoxetine and
venlafaxine
Freeman et al.,
2000 [21]
UK
Venlafaxine vs.
SSRIs,
TCAs
CEA;
decision-
tree
6 months,
payer
perspective
Treatment
success,
SFDs
f
Response: 50%
improve-ment in
HAMD or MADRS
Meta-analysis Univariate,
probabilistic
Venlafaxine dominated
a
SSRIs and TCAs
Haby et al.,
2004 [22]
Australia
CBT vs.
SSRIs
CEA;
decision-
tree
9 months,
payer
perspective
DALYs Multiple outcomes
averaged for
individual studies
Meta-analysis Probabilistic CBT provided by public
psychologist was the
most cost-effective
option
Hemels et al.,
2004 [23]
Austria
Escitalopram
vs.
citalopram
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success
Remission: MADRS ≤
12
8-week head-
to-head trial
Univariate,
probabilistic
Escitalopram
dominated
a citalopram
Howard and
Knight, 2004
[24]
Austria
Venlafaxine ER,
venlafaxine IR,
SSRIs
CEA;
decision-
tree
16 week,
payer
perspective
SFDs
f Remission: not
explicitly reported
Meta-analysis Probabilistic Venlafaxine ER was cost-
effective vs. venlafaxine
IR and SSRIs; SSRIs were
least cost-effective
Kongsakon
and
Bunchapat-
tanasakda,
2008 [25]
Thailand
Escitalopram
vs.
fluoxetine,
venlafaxine
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success
Remission: MADRS ≤
12
2 meta-
analyses
i
Univariate,
probabilistic
Escitalopram
dominated
a fluoxetine
and venlafaxine
Kulp et al.,
2005 [26]
Germany
Escitalopram
vs.
venlafaxine ER
CEA;
Markov
structure;
2-week
cycle
70 days,
payer
perspective
Treatment
success
Response: > 50%
improve-ment in
MADRS
Partial response: 25-
50%
No response: < 25%
8 week head-
to-head trial
None Escitalopram was cost-
effective vs. venlafaxine
ER
Lenox-Smith
et al., 2004
[27]
UK
Venlafaxine vs.
TCAs,
SSRIs
(fluoxetine,
paroxetine,
and
fluvoxamine)
CEA;
decision-
tree
6 months,
payer
perspective
SFDs
f Remission: 17-
HAMD ≤ 7
Response: ≥ 50%
improve-ment in
HAMD-21
Meta-analysis
and a single
study
Univariate Venlafaxine dominated
a
SSRIs and TCAs
Lenox-Smith
et al., 2009
[28]
UK
Venlafaxine vs.
fluoxetine,
amitriptyline
CUA;
decision-
tree
6 months,
payer
perspective
QALYs Remission: HAMD-17
≤ 7
Response: ≥ 50%
improve-ment in
HAMD-17
Pooled data
from 13
clinical trials
Univariate Venlafaxine dominated
a
fluoxetine and
amitriptyline; fluoxetine
dominated
a amitriptyline
Löthgren et
al., 2004 [29]
Sweden
Escitalopram
vs.
citalopram,
venlafaxine
CEA;
decision-
tree
6 months,
payer and
societal
perspective
Treatment
success
Remission: MADRS ≤
12
Meta-analysis Univariate,
probabilistic
Escitalopram
dominated
a citalopram
and venlafaxine
Machado et
al., 2007 [30]
Brazil
SNRIs vs. SSRIs,
TCAs
CEA;
decision-
tree
6 months,
payer
perspective
Treatment
success
Remission: score ≤ 7
on HAMD or ≤ 12
on MADRS
Meta-analysis Univariate,
probabilistic
SNRIs dominated
a SSRIs
and TCAs
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Malone, 2007
[31]
US
SSRIs,
escitalopram,
paroxetine CR,
sertraline,
venlafaxine ER
CEA;
structure
not
explicitly
reported
6 months,
payer
perspective
Treatment
success
Response: ≥ 50%
improve-ment in
HAMD or MADRS
Remission: HAMD ≤
7 or MADRS ≤ 10
Pooled
analysis of
trials
Univariate,
probabilistic
Venlafaxine had the
lowest ICER followed by
escitalopram and
sertraline
j; paroxetine
was dominated
k
Nuijten, 2001
[32]
The
Netherlands
Prolongation
of
antidepressant
medication vs.
no
prolongation
CUA;
Markov
structure;
8-week
cycle
9 months,
payer and
societal
perspec-
tives
QALYs,
TWD
Not explicitly
reported
Published
literature
Univariate Continuation treatment
was not cost-effective,
unless extended to
maintenance
Perlis et al.,
2009 [33]
US
Test for SSRI
responsive-
ness vs.
no test
CUA;
Markov
structure;
3-month
cycle
3 years,
societal
perspective
QALYs Remission:
Instrument not
explicitly reported
STAR*D trial
[34]
Univariate,
two-way
The ICER for the genetic
test would not be
considered cost effective
Sado et al.,
2009 [35]
Japan
COMBI vs.
AD
CUA;
decision-
tree
12 months,
payer and
societal
perspec-
tives
Treatment
success,
QALYs
No response: HRSD-
17 > 6 or HRSD-24
>8
Meta-analysis
of 8 RCTs
Univariate,
probabilistic
COMBI was cost-
effective
Simon et al.,
2006 [36]
UK
COMBI vs.
AD
CUA;
decision-
tree
15 months,
payer
perspective
Treatment
success,
QALYs
Remission: HRSD-17
≤ 6 or HRSD-24 ≤ 8
Meta-analysis Univariate,
probabilistic
COMBI was cost-
effective
Sobocki et al.,
2008 [37]
Sweden
Venlafaxine
maintenance
treatment vs.
placebo
CUA;
Markov
structure;
1-month
cycle
2 years,
payer and
societal
perspec-
tives
QALYs Time to recurrence:
17-HAMD > 12 and
≥ 50% improve-
ment in 17-HAMD
2-year trial Univariate,
probabilistic
Maintenance treatment
with venlafaxine was
cost-effective
Sorenson et
al., 2007 [38]
Denmark
Escitalopram
vs.
citalopram,
venlafaxine ER
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success
Remission: MADRS ≤
12
Meta-analysis Univariate,
probabilistic
Escitalopram
dominated
a citalopram;
similar cost-effectiveness
vs. venlafaxine ER
Sullivan et al.,
2004 [39]
US
Escitalopram,
citalopram,
fluoxetine,
venlafaxine ER,
sertraline,
paroxetine,
paroxetine CR,
venlafaxine
CUA;
decision-
tree
6 months,
payer
perspective
QALYs Response: > 50%
improve-ment in
MADRS (with
treatment
maintained for ≥
180 days)
N/A
l Univariate,
probabilistic
Escitalopram
dominated
a all
treatments
m
Trivedi et al.,
2004 [40]
US
Venlafaxine ER
vs.
SSRIs
(fluvoxamine,
fluoxetine,
paroxetine)
CUA;
decision-
tree
8 weeks,
payer
perspective
QADs and
DFDs
Response: HAMD <
15 and/or ≥ 50%
improve-ment in
HAMD. Remission:
HAMD ≤ 7
Response without
remission: HAMD 8-
14
Pooled
analysis of 8
RCTs
Probabilistic Venlafaxine ER was cost-
effective vs. SSRIs
van Baardewijk
et al., 2005
[41]
Canada
Duloxetine vs.
venlafaxine ER
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success,
SFDs
Remission: HAMD ≤
7 or MADRS ≤ 10
Meta-analysis Univariate,
probabilistic
Venlafaxine ER
dominated
a duloxetine
Vos et al.,
2005 [42]
Australia
Listed in
footnote
n
CEA;
decision-
tree
9 months
and 5 years,
payer
perspective
DALYs Multiple outcomes Meta-
analyses
Probabilistic All interventions had a
favourable ICER under
Australian health service
conditions
Wade et al.,
2005 [43]
UK
Escitalopram
vs.
citalopram,
venlafaxine
CEA;
decision-
tree
6 months,
payer and
societal
perspective
Treatment
success
Remission: MADRS ≤
12
Meta-analysis Univariate,
probabilistic
Escitalopram
dominated
a citalopram;
similar cost-effectiveness
vs. venlafaxine
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Poland, Spain, Sweden, Switzerland, UK, US, and Vene-
zuela) and performed a clinical management analysis to
estimate the country-specific treatment options and out-
comes within the set structure of the decision-tree
model in Figure 3. Lenox-Smith and colleagues [27,28]
amended the structure by including an extra arm repre-
senting a clinical outcome node where patient could
experience improvement without achieving remission.
The main difference in the model structures reported
by Casciano and colleagues [15] and Francois and col-
leagues [19] is that the latter structure included two
p a t h s ,o n ef o rp r i m a r yc a r ea n do n ef o rs e c o n d a r yc a r e .
Another difference is that these models incorporated
different options for patients failing first and second
lines of treatment. The Francois structure offered the
option of hospitalisation once all treatment options have
been exhausted. For patients experiencing remission, the
Casciano structure assumed continuation on treatment
for 6 months, whereas the Francois structure
incorporated a risk of premature treatment discontinua-
tion. Unlike models based on the structure reported in
Francois [19], models adapting the structure by Cas-
ciano [15] did not incorporate rates of suicide or suicide
attempts.
The systematic review identified 8 models
[9-11,16,26,32,33,37] that were described as having a
Markov structure. Time horizons ranged from 70 days
[26] to lifetime [10], longer than the time horizons in
decision-tree models. The cycle lengths of the Markov
m o d e l sr a n g e df r o m1w e e k[ 9 ]t o6m o n t h s[ 1 0 ] .A
variety of health states were defined. In the model by
Aziz and colleagues [10], health states were wellness
(full remission), partial depression (partial remission),
depression (no response), death by suicide, or death by
other cause. Benedict and colleagues [11] included
relapse, recurrence, and treatment switches. Dardennes
and colleagues [16] distinguished between remission
with follow-up and remission without follow-up. The
model by Perlis and colleagues [33] simply used
Table 1 Summary of methods and conclusions of included studies (Continued)
Wade et al.,
2005 [44]
UK
Escitalopram
vs.
citalopram
CEA;
decision-
tree
6 months,
payer and
societal
perspec-
tives
Treatment
success
Remission: MADRS ≤
12
Response: ≥ 50%
improve-ment in
MADRS
Meta-analysis Univariate,
probabilistic
Escitalopram
dominated
a citalopram
Xie et al., 2009
[45]
Singapore
Escitalopram
vs.
venlafaxine,
fluvoxamine
CEA;
decision-
tree
6 months,
societal
perspective
Treatment
success
Remission: MADRS
score ≤ 12
Head-to-head
trials
o
Univariate,
probabilistic
Escitalopram
dominated
a venlafaxine
and fluvoxamine
AD = antidepressant therapy; CEA = cost-effectiveness analysis; CBT = cognitive behavioural therapy; CGI = Clinical Global Impression; COMBI = combination
therapy; CR = controlled release; CUA = cost-utility analysis; DALY = disability-adjusted life-years; DFD = disease-free day; ER = extended release; HAMD =
Hamilton Depression Rating Scale; HDRS = Hamilton Depression Rating Scale; HRSD = Hamilton Rating Scale for Depression; ICER = incremental cost-effectiveness
ratio; IR = instant release; MADRS = Montgomery Åsberg Depression Rating Scale; MDD = major depressive disorder; MECT = maintenance electroconvulsive
therapy; MPT = maintenance pharmacotherapy; N/A = not applicable; QAD = quality-adjusted day; QALW = quality-adjusted life week; QALY = quality-adjusted
life-year; RCT = randomised controlled trial; SFD = symptom-free day; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake
inhibitor; STAR*D = Sequenced Treatment Alternatives to Relieve Depression trial; TCA = tricyclic antidepressants; TWD = time without depression; UK = United
Kingdom; US = United States; WTP = willingness to pay.
a A dominant therapy is less expensive and more effective than the comparator.
b MPT is compared with MECT in elderly individuals with MDD who relapsed after responding to initial course of electroconvulsive therapy.
c Included 6 placebo-controlled RCTs with SSRIs as active arm comparators and 2 head-to-head venlafaxine trials; a meta-analysis was used to obtain response
and remission rates for mirtazapine.
d In the absence of efficacy data for mirtazapine in patients with more severe illness, mirtazapine rates were calculated by applying the mean differences
between the less severe and the more severe population to the mirtazapine rates reported in the meta-analysis for the patient population with HAMD-17 ≥ 18.
e Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, UK, US, Venezuela.
f SFDs were measured as time elapsed after the determination of success through the end of the period being analysed.
g Continuous treatment with milnacipran.
h Follow-up with no preventive treatment.
i Due to lack of published data on head-to-head comparison of escitalopram and fluoxetine, the clinical data comparing escitalopram to citalopram were used as
a proxy, derived from a published meta-analysis.
j ICERs were calculated using SSRIs as the reference group.
k A therapy dominated by other comparators has higher cost and lower effectiveness.
l Due to a lack of consistent and comprehensive studies demonstrating differences in efficacy across all 8 serotonin reuptake inhibitors, and in order to retain a
specific focus on the impact of adverse drug reactions on treatment costs, it was assumed that on average 60% of patients respond to serotonin reuptake
inhibitor therapy.
m Escitalopram had lowest direct costs and the greatest effectiveness, followed by citalopram, generic fluoxetine, venlafaxine ER, sertraline, generic paroxetine,
paroxetine CR, and venlafaxine IR.
n SSRIs (acute, continuation, maintenance), TCAs (acute, continuation, maintenance), Bibliotherapy (acute), Acute and maintenance: individual CBT public
psychologist, individual CBT, private psychologist, individual CBT public psychiatrist, individual CBT private psychiatrist, group CBT public psychologist.
o Due to lack of data on head-to-head comparisons of escitalopram and fluvoxamine, a head-to-head comparison of citalopram and fluvoxamine was used as a
proxy.
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Page 8 of 18“depressed” (on or off therapy) and “well” (on or off
therapy).
Model time horizon
A number of economic evaluation guidelines state that
the model time horizon is dependent upon the time at
which full benefits of the studied intervention can be
realised [47,48]. With treatment of depression, certain
treatment benefit can be realised over a shorter or a
longer time horizon, depending on the treatment stage
(Figure 4) [49].
The treatment phases include acute treatment, during
which time the goal is to resolve symptoms; continua-
tion treatment, during which time therapy is continued
to ensure complete resolution of the index episode and
to prevent relapse; and long-term maintenance, during
which time optimal therapy is continued to prevent the
development of a new episode [50]. Clinical trials in
MDD are often conducted over a period of a few weeks,
typically 6 to 8 weeks [51], representing the acute phase
of a depressive disorder. All three treatment phases
should be implemented to optimise treatment outcome
[49]. If no improvement is observed after a few weeks of
medication, or if undesirable adverse events have
occurred, it is recommended to consider titration of the
prescribed dose or switch to a different antidepressant.
Where improvement is observed, it is recommended to
continue the medication until the underlying depression
has disappeared [38]. The majority of the identified
models had a time horizon of 6 months, covering the
Figure 3 Model structure reported by Casciano et al., 2000. ADR = adverse drug reaction; ECT = electroconvulsive therapy; Rx =
prescription. Reproduced from Casciano et al. (2000) [15]. Image reprinted with permission from Medscape.com, 2010. Available at: http://www.
medscape.com/viewarticle/409930.
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Page 9 of 18acute and continuation phases, or the length of time
that patients with a first episode of MDD should nor-
mally be treated [27]. Three studies adopted a time hori-
zon of less than 6 months [24,26,40], and three models
used a time horizon of 1 year [9,16,35]; other time hori-
zons applied in the identified models included lifetime
[10], 3 years [33], 2 years [37], and 15 months [36].
Patient population
The majority of the models were constructed in a popu-
lation of adults with MDD who were starting initial
therapy, with one study in children and adolescents [22].
No studies were identified in patients with MDD experi-
encing partial response to initial therapy. Two studies
were in patients who did not respond to initial therapy
[11,31], two studies were in patients with recurrent
depression [16,37], one study was in elderly patients
who responded to a course of ECT but then relapsed
[10].
Model comparators
The comparisons of MDD treatments evaluated in 30 of
the included models focusing on acute and continuation
phases are presented in Figure 5. Venlafaxine and escita-
lopram are the most intensively studied interventions,
evaluated in 21 and 15 studies, respectively; followed by
SSRIs as a drug class, which were examined in 10 stu-
dies, and TCAs as a drug class, which were compared in
6 studies. A number of studies (7 of 37) included treat-
ment evaluations during the maintenance phase.
Sobocki and colleagues [37] evaluated venlafaxine main-
tenance treatment versus placebo. One model [35] com-
pared combination therapy with antidepressant therapy
alone. Aziz and colleagues [10] examined maintenance
pharmacotherapy versus maintenance ECT. Dardennes
and colleagues [16] compared preventative strategy (i.e.,
a maintenance treatment with milnacipran) and episodic
strategy (i.e., medical follow-up treating new episodes
when diagnosed). One study [42] included multiple
comparisons of treatments in acute and continuation
phases (SSRIs, TCAs, CBT, and bibliotherapy) and in
maintenance phase (TCAs, SSRIs, and various CBT
options). Perlis and colleagues [33] assessed the cost-
effectiveness of a pharmacogenetic test for SSRI respon-
siveness versus a ‘no-test’ condition. Nuijten [32]
assessed the cost-effectiveness of continuation treatment
with SSRIs compared with no preventative treatment
and examined the impact of extending the continuation
treatment to maintenance treatment in a scenario
analysis.
Efficacy and safety data
Both response and remission rates were applied in the
economic models as measures of treatment success.
However, the definitions of remission and response were
not applied consistently across the studies.
Response was most commonly defined as a 50% or
greater improvement in the Montgomery Asberg
Depression Rating Scale (MADRS) [52] score or the
Hamilton Rating Scale for Depression (HAMD-17) score
Figure 4 Phases of treatment for MDD. MDD = major depressive disorder. Adapted, with permission, from Bakish et al. [49].
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Page 10 of 18[53]. One study [13] defined response as a 50% or
greater improvement in the 21-item HAMD score or a
score of 1 or 2 on the patient-rated Clinical Global
Impression scale [54]. One study used non-response,
defined as a score greater than 6 on the HAMD-17
scale (or greater than 8 on the HAMD-24). One model
[26] used three definitions for varying levels of response
based on MADRS scale: response (greater than 50%
improvement from baseline), partial response (25%-50%
improvement from baseline) and no response (< 25%
improvement from baseline).
General consensus suggests that values of 7 or less on
the HAMD are indicative of clinical remission; for the
MADRS instrument, many clinicians have come to
accept that values of 10 or less are likely to indicate
remission [31]. From the identified models, five studies
[9,12,27,28,40] used clinical data that defined remission
as a score of 7 or less on HAMD, 10 studies
[17,19,20,23,25,29,38,43-45] incorporated remission
defined as score of 12 or less on MADRS, two studies
[9,30] used both of these definitions, and one study [36]
defined remission as a score of 8 or less on the HAMD-
24 or a score of 6 or less on the HAMD-17. Out of 14
models using the MADRS-based definition of remission,
only two [31,41] used a cut-off value of ≤ 10, with the
majority of the models using a cut-off value of ≤ 12.
The variability in the definitions of remission and
response applied across the stu d i e sp r e s e n t sc h a l l e n g e s
in performing indirect comparisons of interventions
where no head-to-head studies exist. As a result, the
majority of studies derived primary clinical inputs from
single trials [8,13,16,23,26,33,37,45] or via simple pool-
ing of data from multiple trials [9,28,31,40], or a combi-
nation of single trials, pooled analyses, indirect
comparisons and meta-analyses [11,12,18-20,25,27]. A
fair amount of models (15 of 37) used meta-analyses to
obtain primary efficacy inputs [14,15,17,21,22,24,29,
30,35,36,38,41-44]. The majority of models (26 of 37)
incorporated adverse events; 23 models included adverse
events as an outcome leading to treatment discontinua-
tion; only 3 studies [8,9,39] modelled the impact of indi-
vidual adverse events in terms of utility and costs.
Efficacy data applied after change of treatment were most
commonly obtained from expert opinion or published lit-
erature. Duration of trials used in the models as sources
of clinical data were typically between 6 and 12 weeks.
Figure 5 Diagram of main comparisons included in the review. AD = antidepressant therapy; ami = amitriptyline; CBT = cognitive
behavioral therapy; cit = citalopram; COMBI = combination therapy; Dul = duloxetine; Esc = escitalopram; Fluo = fluoxetine; Fluv = fluvoxamine;
Mir = mirtazapine; Par = paroxetine; Ser = sertraline; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake
inhibitor; TCAs = tricyclic antidepressants; Ven = venlafaxine.
a Includes both venlafaxine instant release and extended release.
b Includes both
generic paroxetine and paroxetine controlled release.
c Of these 9 studies, 2 studies [14,18] compared venlafaxine with SSRIs in outpatient and
inpatient settings in 10 countries.
d Of these 5 studies, 2 studies [14,18] compared venlafaxine with TCAs in outpatient and inpatient settings in
10 countries.
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Resource use and cost estimates used in the identified
analyses were predominantly obtained and/or validated
by expert opinion (22 of 37). Malone and colleagues
[31] applied 6-month resource use and costs estimates
from a retrospective analysis of accounting records of
1,814 patients enrolled in nine randomised, controlled
trials [55]. Sobocki and colleagues [37] used cost data
from the naturalistic observational study Health Eco-
nomic Aspects of Depression in Sweden, conducted in
Swedish primary care [56]. For primary care, Wade and
colleagues [43] used resource use and cost estimates
from the UK General Practice Research Database analy-
sis. Two studies [33,39] used prospective cohort studies
in estimating resource use and costs.
The majority of studies employing a payer perspective
included medication costs, costs of physicians’ time,
diagnostic and monitoring tests, hospitalisation and psy-
chotherapy. The specific resources applied varied sub-
stantially between the studies. Only a few studies
reported the costs of managing adverse events, which
were included in the base-case analyses [8,9,12,24,25,39].
A number of studies [10,16,17,19,20,23,25,29,33,43,44]
reported the cost of suicide and/or suicide attempt.
Almost half of the identified studies conducted their
analyses from the societal perspective. The majority of
studies estimated indirect costs associated with produc-
tivity losses using the Human Capital approach
[11,19,20,23,25,29,38,41,43-45], and a few used the Fric-
tion Costs approach [17,32]. The US study in elderly
patients with recurrent MDD also included costs asso-
ciated with lost leisure time activities and wages lost by
caregivers [10].
Health state utilities
Of the identified models, 14 included utility weight esti-
mates to calculate quality-adjusted life-years (QALYs).
The utility values applied in the models varied across
the same health states by between 0.11 and 0.21, sug-
gesting that the utility weights applied in the models
were not consistent (Table 2) [57-68]. Revicki and
Wood [62] was the most commonly cited source of uti-
lity values applied in the models. This study used the
HAMD, SF-36 Health Survey, and standard gamble
interviews to obtain utilities for 11 hypothetical depres-
sion-related states varying by depression severity (i.e.,
mild, moderate, severe), medication (i.e., nefazodone,
fluoxetine, imipramine), and treatment status (i.e., main-
tenance treatment or no treatment). The mean utility
for severe, untreated depression was the lowest, 0.30.
The highest mean utility was for remission without
treatment, 0.86. Medication-specific utilities varied from
0.55 to 0.63 for moderate depression, 0.64 to 0.73 for
mild depression, and 0.72 to 0.83 for antidepressant
remission maintenance therapy [62]. The study by
Simon and colleagues [36] used these estimates in the
base case analysis, and in the sensitivity analysis the
study investigated the effect of partial response to treat-
ment using uncertainty ranges of 0.30 to 0.63 and 0.63
to 0.70 for severe and moderate depression, respectively.
The study highlighted the scarcity of evidence on the
health-related quality of life of people with depression.
Benedict and colleagues [11] used utilities derived
from the EuroQol Five Dimension instrument [69]
scores of approximately 300 European patients repre-
senting the head-to-head clinical trial population. The
model used utility values of 0.79 for remitters, 0.68 for
responders, 0.55 for non-responders, and 0.53 for those
dropping out. Utility of patients achieving remission and
staying in remission without treatment (0.86) was
obtained from Revicki and Wood [62]. Another UK
model [28] used the methodology by Lave and collea-
gues [68] to transform the disease-free days (DFDs) into
utility weights. The number of DFDs between measure-
ments over any given interval was first estimated by
adding the calculated number of DFDs for the first and
second HAMD-17 scores, dividing by two, and multiply-
ing by the number of days between assessments. The
QALYs gained were then estimated assuming a gain of
0.41 of a quality-adjusted day for each whole DFD
gained. One model [40] transformed DFDs into quality-
adjusted days using utility weights from Lave and collea-
gues [68].
Cost-effectiveness results and uncertainty
The findings of the reviewed models are presented in
Table 1. The results for the most studied interventions
appear to be fairly consistent. Escitalopram was domi-
nant over sertraline (in 2 of 3 analyses [8,39]), duloxe-
tine (in 1 analysis [9]), cital o p r a m( i n9o f9a n a l y s e s
[17,19,20,23,29,38,39,43,44]), fluoxetine (in 4 of 4 ana-
lyses [19,20,25,39]), fluvoxamine (in 1 analysis [45]),
generic and controlled-release paroxetine (in 3 of 3
comparisons [31,39]), and venlafaxine extended release
(ER) and instant release (IR) (in 7 of 12 comparisons
[19,20,25,29,39,45]). Escitalopram was cost-effective
compared with sertraline [31], SSRIs [31], and venlafax-
ine [17,26]. Escitalopram had similar cost-effectiveness
to venlafaxine in two comparisons [38,43] and was less
cost-effective in one [31]. Apart from escitalopram, ven-
lafaxine was commonly compared with SSRIs and TCAs
and was a dominant strategy in the majority of these
comparisons. Among the two studies identified compar-
ing individual SNRIs, duloxetine was dominant over
venlafaxine in one comparison [11] and venlafaxine was
dominant over duloxetine in the other comparison [41].
All but one study [26] explored parameter uncertainty.
Univariate sensitivity analyses were performed in all of
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Page 12 of 18Table 2 Health-state utility values applied in published models in MDD
Author, year Utility value by health
state
a
Primary source and method of utility estimation
Armstrong et al., 2008 [9]; Armstrong
et al., 2007 [8]
Treated depression: 0.848
Untreated depression: 0.58
Sullivan et al. [39]: EQ-5D
b
Aziz et al., 2005 [10] Pharmacotherapy:
Depression: 0.43
Partial depression: 0.55
Well: 0.75
ECT:
Depression: 0.52
Partial depression: 0.66
Well: 0.90
Multiple sources:
Hatziandreu et al. [57]; Mazumdar et al. [58]; Judd et al. [59]; McDonald et al.
[60], Sackett and Torrence [61]
Benedict et al., 2010 [11] Remitters: 0.79
Responders: 0.68
Non-responders: 0.55
Staying in remission: 0.86
Multiple sources:
Eli Lilly, HMBU trial
c (data on file): EQ-5D; Revicki and Wood [62]: standard
gamble
d
Dardennes et al., 2000 [16] Remission with follow-up
Preventive strategy: 0.875
Episodic strategy: 0.895
Remission without follow-
up: 0.895
e
Recurrence first 2 months:
0.306
e
Recurrence months 3 and
4: 0.725
e
Recurrence months 5 and
6:0.795
e
Anton and Revicki [63]: standard gamble
f
Nuijten, 2001 [32] Depression, on treatment
SSRI: 0.70, TCA: 0.64
In remission, treatment
prolongation
SSRI: 0.80, TCA: 0.72
In remission, off treatment:
0.86
Severe depression: 0.30
Revicki and Wood [62]: standard gamble
d
Perlis et al., 2009 [33] Recovered
Not on treatment: 0.88
Disutility of treatment: 0.04
Depressed
Not on treatment: 0.63
Disutility on treatment:
0.04
Multiple sources:
Bennett et al. [64]; Revicki et al. [65]; Revicki and Wood [62]: standard gamble
d;
Schaffer et al. [66]
Sado et al., 2009 [35] Severe depression: 0.30
g
Moderate depression: 0.63
g
Response on treatment:
0.80
g
Response, no treatment:
0.86
g
Revicki and Wood [62]: standard gamble
d
Simon et al., 2006 [36] Severe depression: 0.30
Moderate depression: 0.63
Remission, treatment: 0.80
Remission, no treatment:
0.86
Revicki and Wood [62]: standard gamble
d
Sobocki et al., 2008 [37] Well: 0.86
Episode: 0.57
Remission: 0.81
Sobocki et al. [67]:
The study administered EQ-5D questionnaire to 447 patients treated with
antidepressant in primary care.
Sullivan et al., 2004 [39] Treated depression: 0.848
Untreated depression
decrement:
-0.268
Decrements for ADRs were
applied
h
Sullivan et al. [39]: EQ-5D
b
ADR = adverse drug reaction; DFD = disease-free day; ECT = electroconvulsive therapy; EQ-5D = the EuroQol Five Dimension instrument; GI = gastrointestinal;
MDD = major depressive disorder; MEPS = Medical Expenditure Panel Survey; QAD = quality-adjusted day; SG = standard gamble, SSRI = selective serotonin
reuptake inhibitor; TCA = tricyclic antidepressant; UK = United Kingdom.
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Page 13 of 18these studies. Probabilistic sensitivity analyses were per-
formed in approximately three-quarters of studies. Cost-
effectiveness acceptability curves are used in economic
analyses to incorporate the joint uncertainty about the
effects and costs [70]; these were presented in 5 of 37
studies [8,11,35-37]. Of the 36 studies, 26 conducted
comprehensive sensitivity analyses incorporating all
important variables. In 14 of these 26 studies, results
were not substantially altered in the sensitivity analyses.
In 11 studies, varying clinical input parameters impacted
the results while in 7 studies, varying resource use or
cost parameters changed the results. Of the 26 studies
with the comprehensive sensitivity analyses, eight were
the cost-utility studies, of which only two showed sensi-
tivity to changes in utility weights.
Discussion
We reported the main methodological elements of the
published decision-analytic models in MDD. The major-
ity of the reviewed models used a decision-tree struc-
ture, largely because the analyses explored the acute and
continuation phases of depression and relied on clinical
inputs from trials of 6 to 12 weeks in duration. Deci-
sion-tree models are appropriate for economic model-
ling in acute illnesses; however, Markov models are the
first choice for pharmacoeconomic analysis of chronic
diseases like depression [32]. Markov models provide
the advantage over decision-tree models by being able
to incorporate longer time horizons, which might be
more appropriate given the recurrent nature of depres-
sion. The fact that the decision-tree structure is com-
monly preferred over the Markov structure can be
explained by the existing data gaps in the clinical evi-
dence necessary to populate a longer horizon multi-state
model. A model design combining both the decision-
tree and Markov structures could be utilised to accu-
rately capture the short-term trial data for the acute
phase and a longer-term events in the maintenance
phase.
Only 18 of 37 studies were conducted from the socie-
tal perspective. Both utilisation of health care services
and productivity losses are high within the MDD patient
population, therefore, it is important to consider a
broad cost perspective that captures all of the relevant
costs to society. Evidence suggests that employment sta-
tus is more rapidly affected by depression compared
with its effect on utilisation of health care services
[71,72]. The review of the models suggests that indirect
costs have a substantial impact on the outcome of the
analysis. In calculation of indirect costs, most models
included productivity loss due to absenteeism from
work. Productivity loss due to presenteeism (i.e., loss
due to patients suffering from symptoms of depression
at work resulting in reduced productivity) is also pro-
found [73,74]. Costs associated with lost productivity
while at work were examined by one model in the sensi-
tivity analysis [37].
The review identified 14 economic analyses that
included QALY as a main outcome. The purpose of
QALYs is to provide a value- or preference-based out-
come measure incorporating trade-offs between quality
of life and quantity of life in a common metric [75]. In
recent decades, QALY has become the dominant mea-
sure of health value in health technology assessment
[76]. Current evidence on the health-related quality of
life utilised by the identified models appeared to be
scarce, particularly for partial response.
There is a need for further cost-effectiveness studies in
patients with MDD who have had partial or no response
to the first-line therapy. This review revealed a lack of
clinical data in inadequate responders to inform such
economic models. More studies focusing on evaluating
adjunctive MDD therapies would be welcome. The lack
of long-term data describing costs and outcomes
a Note that some of the studies applied utility values but did not report these explicitly. Francois et al. [19] did not report the utility weights, but stated the
source for these as Quality of Life Perspective Study, Lundbeck (data on file). Lenox-Smith et al. [28] transformed DFDs into utility weights using the
methodology from Lave et al. [68] using the following assumptions: a non-depressed subject was assumed to have utility score of 1.0 (perfect health); a subject
with major depression was assumed to have a utility score of 0.59 (estimated from literature); subjects were assumed to gain 0.41 of QAD for each depression-
free day. Trivedi et al. [40] transformed DFDs into utility weights using the methodology from Lave et al. [68], assuming a gain of 0.2 to 0.41 of QAD for each
DFD.
b Utility values for each health state were derived from a direct analysis of the data in the 2000 MEPS, which provided individual and variance adjustment
weights. The EQ-5D was administered via self-administered questionnaire in MEPS.
c Utility study based on trials (Eli Lilly, HMBU trial, data on file) derived utility values for remitters, responders, and non-responders from EQ-5D scores of
European patients using the UK tariffs.
d Utility of remitters staying in remission was obtained from Revicki and Wood [62]. This study used SG method to generate utilities for 11 hypothetical health
states. Health states were varied by severity and medication; 70 patients with MDD or dysthymia who completed ≥ 8 weeks of antidepressant treatment were
recruited.
e The same values for both episodic strategy and preventative strategy.
f The SG method was used to generate utilities for hypothetical depression-related health states; 70 MDD patients were interviewed cross-sectionally to provide
utilities for these health states.
g Both values for combination therapy and antidepressant therapy were assumed to be the same.
h GI: -0.065; Diarrhoea: -0.044; Dyspepsia: -0.086; Nausea: -0.065; Constipation: -0.065; Sexual: -0.049; Excitation: -0.129; Insomnia: -0.129; Anxiety: -0.129;
Drowsiness: -0.085; Headache: -0.115; Other (average of all ADRs): -0.085.
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models.
The review identified some variability in the methods
used by the current models, which inevitably makes the
interpretation of results more difficult. This variability
was seen around a number of methodological domains.
First, studies applied different modelling approaches,
including both decision-tree and Markov structures.
Second, studies utilised different outcomes, with only 14
studies reporting incremental cost-per-QALY estimates.
Third, resource use and cost components included in
the models varied substantially between the studies, par-
ticularly around the resource use assumptions following
failure of the initial therapy. This partially reflects differ-
ences in health systems; however, also contributing to
this is the absence of a large-scale resource utilisation
study in MDD in any of the countries covered by the
existing analyses. Finally, primary efficacy data used in
the models were derived from single trials, pooled ana-
lyses, indirect comparisons, meta-analyses, or combina-
tions of these. The variation in methodology for
deriving clinical inputs could be explained by the lack of
data for some comparators as well as by the difficulty in
performing indirect comparisons due to differences in
outcome measures between the trials.
D e s p i t es o m ev a r i a b i l i t yi nt h em e t h o d s ,t h er e s u l t s
reported by the identified models were broadly consis-
tent. For venlafaxine, a conflicting result was found in
two comparisons with duloxetine, with one study
reporting venlafaxine ER as a dominant strategy [41]
and one study reporting duloxetine as a dominant strat-
egy compared with venlafaxine ER [11]. Given that all
other studies reported fairly consistent results for venla-
faxine comparisons, this variation could be due to the
differences in patient populations between the two stu-
dies, with the former study evaluating first-line interven-
tions and the latter study evaluating patients who failed
on first-line SSRI. Similarly, another substantial incon-
sistency was observed in one of 12 comparisons of esci-
talopram and venlafaxine [31]. Again, this study
examined second-line interventions, suggesting that the
cost-effectiveness of interventions evaluated as first-line
therapies varies substantially compared with the cost-
effectiveness of these interventions if used as second-
line treatments.
Although model structures varied, overall conclusions
regarding the relative cost-effectiveness of interventions
were largely consistent. A few exceptions to this were
noted. In one study [28], venlafaxine dominated fluoxe-
tine; however, in another study [39], venlafaxine ER was
not cost-effective and venlafaxine IR was dominated by
fluoxetine. Both models had decision-tree structures,
with one [28] using the structure presented by Casciano
[15] and the other [39] modelling the initial treatment
outcomes in stage one and the treatment of adverse
drug reactions in stage two. However, the inconsistency
in results also could be due to the use of different mea-
sures of response. In comparisons of venlafaxine with
SSRIs, one study reported venlafaxine to be dominant
[27] while another found venlafaxine to be cost-effective
[24]. Both models had decision-tree structures. The
longer time horizon in the first study (6 months [27] as
opposed to 16 weeks [24]) may have contributed to this
difference. Given other parameter differences between
these models, it is difficult to conclude with certainty
whether or not structural uncertainty is an issue.
The results of the economic models were most sensi-
tive to clinical outcomes than to costs or to utility
weights. The uncertainty in key model variables was
examined through the use of one-way sensitivity analy-
sis. In approximately half of the models that conducted
comprehensive sensitivity analyses, the results were con-
firmed to be robust. Even if interpreted correctly, how-
ever, one-way sensitivity analysis will commonly (in the
absence of correlation) underestimate uncertainty, mak-
ing it particularly vulnerable to false claims that results
are robust [77].
Despite the fact that the study by Sullivan and collea-
gues [39] found that drug-related adverse events have a
significant impact on the direct cost and cost-effective-
ness of treatments, only three studies considered differ-
ences in adverse-event profiles of the individual agents
evaluated. Most of the studies modelled discontinuations
due to adverse events, as this is equivalent to treatment
failure.
Our review had several limitations. Firstly, it did not
appraise the quality of the included studies but focused
on reporting the methods and data sources used in the
models. The second limitation is that we restricted our
review to the published literature, therefore excluding
searches of the grey literature. Nonetheless, we believe
our work provides a comprehensive review of economic
models in MDD and could serve as a useful reference
for researchers.
Conclusions
Our review indicated that over the last 10 years a con-
siderable number of economic models have been devel-
oped to evaluate the cost and benefits of the
interventions for the treatment of MDD. The identified
models varied somewhat in their methodology, but the
results seemed broadly consistent. In terms of the
model input data, the review identified several data
gaps, including utility in partial responders, efficacy of
second-line treatments, and utilisation estimates
obtained from high-quality sources (for example, from
observational studies). The review highlighted the diffi-
culty in performing indirect comparisons due to
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trials. Achieving consistency with this, and consistency
in definitions of health states used in MDD clinical trials
and utility studies, would be a large step forward.
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